Welcome to our dedicated page for Ascentage Pharma Group International SEC filings (Ticker: AAPG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ascentage Pharma Group International furnishes SEC filings as a foreign private issuer reporting under Form 6-K and indicating annual reporting on Form 20-F. The filings document press releases and Hong Kong Stock Exchange announcements for annual results, oncology pipeline updates, clinical and preclinical presentation materials, and changes in corporate administration.
The company’s filing record also includes Hong Kong annual report and environmental, social and governance materials, annual general meeting notices, proxy forms, director re-election matters, general mandates to issue or repurchase shares, and supplemental equity-incentive grant proposals under its RSU and post-IPO share option schemes.
Ascentage Pharma Group International filed a Form 6-K report announcing additional awards granted under its 2021 and 2022 RSU (Restricted Share Unit) Schemes. The report was filed on June 28, 2025, with the announcement dated June 27, 2025.
The filing includes a single exhibit (99.1) containing the detailed announcement of the RSU grants. The document was signed by CEO Dajun Yang. The company, headquartered in Suzhou Industrial Park, China, confirms it files annual reports under Form 20-F.
This filing represents a routine securities disclosure regarding employee compensation arrangements, though specific details of the RSU grants are contained in the referenced exhibit which is not included in the main filing.